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Abstract
The mammalian sirtuin family has attracted tremendous attention over the past few years as stress adaptors
and post-translational modifier. They have involved in diverse cellular processes including DNA repair, energy
metabolism, and tumorigenesis. Notably, genomic instability and metabolic reprogramming are two of
characteristic hallmarks in cancer. In this review, we summarize current knowledge on the functions of sirtuins
mainly regarding DNA repair and energy metabolism, and further discuss the implication of sirtuins in cancer
specifically by regulating genome integrity and cancer-related metabolism.
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Background
Sirtuins, the highly conserved NAD + −dependent en-
zymes, are mammalian homologs of the yeast Sir2 gene
which has been known to promote replicative life span
and mediate gene silencing in yeast [1]. The sirtuin fam-
ily comprises seven proteins denoted as SIRT1-SIRT7,
which share a highly conserved NAD + −binding cata-
lytic domain but vary in N and C-termini (Fig. 1). The
divergent terminal extensions account for their various
subcellular localization, enzymatic activity and binding
targets. SIRT1, SIRT6, and SIRT7, are chiefly nuclear
proteins, while SIRT3, SIRT4 and SIRT5 predominantly
reside in mitochondria and SIRT2 is primarily cytosolic
(Fig. 1). But some of theses proteins are reported to
translocate from their typical compartments under spe-
cific circumstances [2–4]. Besides the well-recognized
deacetylase function, sirtuins have also evolved as mono
ADP ribosyltransferase, lipoamidase (SIRT4), demalony-
lase and desuccinylase (SIRT5) [5, 6].
The host cells are constantly subjected to oxidative,
genotoxic and metabolic stress. The ratio of NAD+/
NADH is correlated with stress resistance, oxidative
metabolism and DNA repair [7]. Sensing intracellular
NAD+ changes, sirtuins are proposed to work as stress
adaptors. Meanwhile, given their diverse enzymatic ac-
tivities, they are described to play critical roles in regu-
lating post-translational modifications (PTMs), among
which acetylation is an important form. Sirtuins deacety-
late a multitude of targets including histones, transcrip-
tion factors, and metabolic enzymes. Taken together,
sirtuins have been implicated in numerous cellular
processes including stress response, DNA repair, energy
metabolism, and tumorigenesis [8, 9].
Aberrant cellular metabolism in cancer cells character-
ized by elevated aerobic glycolysis and extensive glutami-
nolysis [10] is essential to fuel uncontrolled proliferation
and malignant tumor growth. The Warburg effect,
which describes that tumor cells preferentially use glu-
cose for aerobic glycolysis in the presence of ample oxy-
gen [11], has emerged as one of hallmarks of cancer.
Even though originally thought to be energy insufficient,
Warburg effect is now widely accepted to confer rapid
proliferation and invasive properties to tumor cells
[12–14]. In parallel, many cancer cells exhibits enhanced
glutamine metabolism and cannot survive in the absence
of glutamine [15]. Recent studies have shown that a suc-
cession of well-established oncogenic cues, including Myc,
Ras or mammalian target of rapamycin complex 1
(mTORC1) pathways play imperative roles in inducing
glutaminolysis [16–18]. Besides metabolic reprogram-
ming, deregulated DNA-repair pathways and subsequent
genome instability appears to facilitate the acquisition of
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tumorigenic mutations propitious to tumor growth and
cancer progression [19, 20].
Mounting evidence has shed light on that sirtuins play
diverse parts in cancer [1]. In this review, we summarize
an overview and update on the function of sirtuins in
metabolism and DNA repair, and further touch on their




Glucose metabolism encompasses several processes
implicating glucose uptake, utilization, storage and out-
put, which needs elaborate coordination among the
regulating hormone insulin and its counterpart such as
glucagon. Sirtuins are verified to exert various impacts
on gluconeogenesis, glycolysis, insulin secretion and sen-
sitivity bearing therapeutic potential to several metabolic
diseases (Fig. 2).
SIRT1
SIRT1 is the most conserved mammalian NAD + −
dependent protein deacetylase that has emerged as a
regulator of glucose metabolism. As for gluconeogenesis,
the role of SIRT1 is regarded as dual and intricate. In a
short-term fasting phase, SIRT1 induces decreased hep-
atic glucose production by suppressing CRTC2 (CREB-
regulated transcription coactivator 2), a key mediator of
early phase gluconeogenesis [21]. With the fasting phase
prolonged, SIRT1 deacetylates and activates both the
transcription factor FOXO1 (forkhead box protein O1)
and its co-activator PGC1α (Peroxisome proliferator-
activated receptor gamma coactivator 1 α) [22, 23],
which reinforces the gluconeogenic transcriptional pro-
gram. In respect to glycolysis, SIRT1 attenuates the
transcription of glycolytic genes by directly deacetylating
transcription factor HIF1α [24] and also inhibits glycolytic
enzyme PGAM1 (phosphoglycerate mutase 1) through
deactylation [25]. SIRT1 is also implicated in glucose me-
tabolism by functioning as an insulin sensitizer. Through
transcriptionally repressing the uncoupling protein 2
(UCP2), SIRT1 positively modulates glucose-stimulated in-
sulin secretion [26]. Accumulating evidence suggests that
SIRT1 and SIRT1 activators can prevent and reverse insulin
resistance and diabetic complications, proven to be a prom-
ising therapeutic target in type 2 diabetes (T2D) [27–30].
SIRT2
Compared to SIRT1, SIRT2 is predominantly a cytoplas-
mic protein and pretty abundant in adipocytes. SIRT2
activates the rate-limiting enzyme phosphoenolpyruvate
carboxykinase (PEPCK) via deacetylation and enhances
gluconeogenesis during times of glucose deprivation
[31]. Meanwhile recent studies have proposed that, in
regard to insulin sensitivity, SIRT2 may act specific and
opposing roles in different tissues [32].
SIRT3, SIRT4, and SIRT5
Primarily located in mitochondria, SIRT3, SIRT4, and
SIRT5 sense and regulate the energy status in this organ-
elle. Activating glutamate dehydrogenase (GDH), SIRT3
facilitates gluconeogenesis from amino acids [33]. In
addition, SIRT3 indirectly destabilizes transcription
factor HIF1α and subsequently inhibits glycolysis and
glucose oxidation [34]. Intriguingly, recent studies have
shown that SIRT3 levels in pancreatic islets are reduced
in patients afflicted with type 2 diabetes [35] and SIRT3
overexpression in pancreatic β-cells promotes insulin




















Fig. 1 Schematic representation of seven mammalian sirtuins. The shaded area represents NAD+ - dependent catalytic domain. aa, amino acids
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stress that is connected to β-cell dysfunction and
apoptosis [36].
SIRT4, initially reported as a unique ADP-
ribosyltransferase, appears to blunt insulin secretion
by reducing GDH activity [37]. In line with this, the
amino acid-stimulated insulin secretion is upregu-
lated in SIRT4-deficient insulinoma cells [38]. Be-












































Fig. 2 Overview of sirtuins in glucose metabolism. Selected pathways in nucleus, cytosol and mitochondria are depicted. a Located in cytoplasm,
SIRT2 deacetylates the rate-limiting enzyme PEPCK and promotes gluconeogenesis during low nutrient condition. Both SIRT3 and SIRT4 target
GDH in mitochondria but their enzymatic activities seem to be opposite. Besides GDH, SIRT4 also reduces PDH activity which converts pyruvate
to acetyl CoA. SIRT5 facilitates glycolysis via glycolytic enzyme GAPDH and may disrupt glutamine metabolism through GLS. b In respect to the
nuclear sirtuins, both SIRT1 and SIRT6 suppress the transcription factor HIF1α through different manners and subsequently attenuate glycolysis.
The reciprocal activation of FOXO1 and its coactivator PGC-1α by SIRT1 reinforces the gluconeogenic transcription. By contrast, SIRT6 down-
regulates PGC-1α and suppresses hepatic glucose production. PEPCK,phosphoenolpyruvate carboxykinase; GDH,glutamate dehydrogenase;
PDH,pyruvate dehydrogenase; GAPDH,glyceraldehyde phosphate dehydrogenase; GLS,glutaminase; PGC-1α,Peroxisome proliferator-activated
receptor gamma coactivator 1 α; FOXO1,forkhead box protein O1
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identified in the regulation of insulin secretion in-
cluding ADP/ATP carrier proteins, insulin-degrading
enzyme, ANT2 and ANT3 [37]. Interestingly SIRT4
is characterized as a lipoamidase and diminishes
pyruvate dehydrogenase complex (PDH) activity, an
enzyme converting pyruvate to acetyl CoA and con-
necting glycolysis to the TCA cycle [6].
In contrast to other sirtuins, SIRT5 displays deacetylase
and NAD+ −dependent demalonylase and desuccinylase
activities. SIRT5 facilitates glycolysis via demalonylating
the glycolytic enzyme glyceraldehyde phosphate dehydro-
genase (GAPDH) [39]. And a recent study proposed that
SIRT5 might be positively correlated with insulin sensitiv-
ity, the biological significance of which still remains to be
confirmed [40].
SIRT6
There is growing appreciation that SIRT6 plays a critical
role in glucose homeostasis. In the case of gluconeogen-
esis, SIRT6 indirectly suppresses PGC-1α leading to
downregulation of hepatic glucose production [41].
Similar to SIRT1, SIRT6 can also shut down the glyco-
lytic flux by deacetylation of histone H3 lysine 9 (H3K9)
in promoters of glycolytic genes and acting as a HIF1α
corepressor [42]. In this regard, one recent study re-
vealed that the antiglycolytic activity of SIRT6 exerts
beneficial impact against nasal polyp formation [43].
Meanwhile, SIRT6 may positively mediate glucose-
stimulated insulin secretion [44] and overexpression of it
enhances insulin sensitivity in skeletal muscle and liver,
emerging as an attractive therapeutic target for T2D.
SIRT7
SIRT1, SIRT3 and SIRT6, as discussed above, have all
been identified to exert repressive effect on HIF-1 ac-
tivity through different mechanisms. Likewise, it was
reported that Sirt7 overexpression decreased HIF-1α
and HIF-2α protein levels through a distinct mechan-
ism independent of its deacetylase activity [45]. Be-
sides, Sirt7 knockout mice were resistant to glucose
intolerance and insulin sensitivity is improved in Sirt7
knockout mice receiving a high-fat diet [46]. All these
findings revealed a novel role for SIRT7 in glucose
metabolism.
Lipid metabolism
Lipid homeostasis is maintained by a collection of meta-
bolic pathways including hepatic lipogenesis, adipogene-
sis, lipolysis in white adipose tissue (WAT) and lipid
utilization in both liver and skeletal muscle, each of
which is dominant under distinct nutrient condition.
Sirtuins are involved in multiple aspects of lipid me-
tabolism and related diseases as briefly summarized
below (Fig. 3).
SIRT1
In addition to its critical roles in glucose metabolism,
SIRT1 is also convinced to regulate lipid homeostasis.
During fasting, SIRT1 deacetylates and destabilizes sterol
regulatory element binding protein 1 (SREBP1), a hep-
atic transcription factors for lipogenesis and cholesterol
synthesis, which theoretically represses fatty acid and
cholesterol synthesis [47]. In agreement with this, a re-
cent study points out an increase of de novo lipogenesis
upon SIRT1 inhibition in human fetal hepatocytes [48].
Moreover, the complex transcriptional program control-
ling adipogenesis is mainly coordinated by the nuclear
receptor PPARγ. SIRT1 reduces the activity of PPARγ
and suppresses adipogenesis in situation of nutrient de-
pletion, subsequently engendering increased lipolysis
and fat mobilization from WAT [49].
SIRT1 also occupies a special place in lipid metabolism
via enhancing lipid oxidation. In support of this notion,
activation of PPARα and its coactivator PGC1α by
SIRT1 are presented in both liver and skeletal muscle,
which stimulates the expression of β-oxidation related
genes [50, 51]. Of note, AMPK, an energy sensor, is also
involved in fatty acid oxidation in skeletal muscle and its
interaction with SIRT1 is described as a reciprocal regu-
latory loop, in which AMPK upregulates SIRT1 by
boosting NAD+ levels and SIRT1 induces the AMPK
activator [52, 53]. Given its diverse functions in lipid
homeostasis, SIRT1 is a potential therapeutic target to
prevent obesity and liver steatosis and ameliorate cardio-
vascular diseases in obese individuals [54–56].
SIRT2
Similarly to SIRT1, SIRT2 facilitates lipolysis in WAT
under nutrient deprivation by repressing transcriptional
activity of PPARγ [57], and it attenuates lipid synthesis
by suppressing ATP citrate lyase (ACLY), a building
block for hepatic de novo lipogenesis [58], which might
be biologically significant to fatty liver treatment. The
link between SIRT2 and fatty acid oxidation appears to
be elusive, and the development of diet-induced obesity
in mice may be attributed to SIRT2 repression and at-
tendant reduced β-oxidation [59].
SIRT3, SIRT4, and SIRT5
Current studies mainly indicate the role of SIRT3 in
fatty acid oxidation. SIRT3 activates long chain acyl CoA
dehydrogenase (LCAD) [60], a key enzyme involved in
long-chain fatty acids oxidation, triggering β-oxidation
in hepatocytes and skeletal muscle and also promotes
ketogenesis via deacetylating and increasing the activity
of the 3-hydroxy-3-methylglutaryl CoA synthase 2
(HMGCS2) in the liver [61].
In contrast to SIRT3, SIRT4 exhibits a negative regulatory
role towards fatty acid oxidation. Under nutrient-replete



























SREBP1 Lipogenesis related genes
PPAR X Adipogenesis related genes
PGC1





Fig. 3 (See legend on next page.)
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condition, SIRT4 inhibits malonyl CoA decarboxylase
(MCD) in muscle, an enzyme converting malonyl CoA to
acetyl CoA, favoring lipid anabolism [62]. In parallel, SIRT4
decreases PPARα and its target genes activities, conse-
quently repressing fatty acid oxidation in liver [63]. A more
recent study highlighted a novel mechanism that deacety-
lating and destabilizing MTPα, a key enzyme in β-oxidation
by SIRT4 may contribute to the pathogenesis of Non-
alcoholic fatty liver disease (NAFLD) [64].
As a desuccinylase described above, SIRT5-dependent
desuccinylation and activation of the rate-limiting keto-
genic enzyme HMGCS2 may preferentially stimulate ke-
togenesis and reduced fatty acid oxidation was found in
SIRT5 knockout mice [65]. Consistently, downregulated
expression of SIRT5 is detected in the liver of NAFLD
patients [66].
SIRT6
Growing data noted that SIRT6 regulates fat metab-
olism as well. In the control of lipid storage, SIRT6
reduces the expression of PPARγ dependent genes in
adipocytes and overexpression of SIRT6 reverses the
detrimental outcome induced by high-fat diet in
mice [67]. Additionally, fatty liver and decreased
fatty acid oxidation can be seen in liver-specific
SIRT6 deletion mice [68], which implies its positive
function upon lipogenesis and hepatic β-oxidation. A
compelling study even presented that SIRT6 is associ-
ated with cholesterol homeostasis by negatively influ-
encing lipogenic transcription factors SREBP1 and
SREBP2 [69].
SIRT7
SIRT7, regarded as a deacetylase, is hypothesized to
link lipid metabolism, even though the recent find-
ings are perplexing and contradictory. The result of
Shin et al. indicated Sirt7 knockout mice would de-
velop liver steatosis due to deregulated ER stress
[70], while Yoshizawa and colleagues concluded
SIRT7-deficient mice were resistant to fatty liver and
SIRT7 increases lipogenesis and fat accumulation
[46]. Accordingly, the underlying mechanism clearly
merits further study.
Glutamine metabolism
Compared to quiescent cells, proliferating cells prefer to
use crucial intermediates derived from tricarboxylic acid
(TCA) cycle for biomass building that supports the cell
growth and division. Thus, a process called anaplerosis
is required to compensate the TCA cycle intermediates,
for which glutamine is the main source. In particular,
carbon from glutamine contributes to amino acid and
fatty acid synthesis while the nitrogen from glutamine is
used for nucleotide biosynthesis. During this replenish-
ment, glutamine is firstly converted into glutamate by
glutaminase that exists in two versions in mammals,
kidney-type glutaminase (GLS) and liver-type glutamin-
ase (GLS2). Glutamate is further converted to TCA cycle
intermediates α-ketoglutarate either by glutamate de-
hydrogenase (GDH) or aminotransferases [71].
A succession of oncogenotypes instigate the upregu-
lated glutamine metabolism [16–18]. The MYC may be
the most common oncogene associated with glutamine
metabolic rewiring. The oncogenic transcription factor
c-Myc, which is known to stimulate cell proliferation
through miRNAs regulation, was found to transcription-
ally repress miR-23a and miR-23b resulting in a greater
expression of their target protein GLS [72] and an en-
hanced glutamine-fuelled anaplerosis.
Apart from affected by many oncogenic mutations,
glutamine enzymes are also controlled through post-
translational modifications. SIRT3 might be associated
with glutamine metabolism by augmenting the activities
of GDH [33] and GLS2 [73] through deacetylation.
SIRT4, as mentioned above, inhibits GDH activity by
ADP-ribosylation and consequently mediates reduction
in glutamine metabolism, which appears to be tumor
suppressive as discussed below. Interestingly, SIRT5
might be involved in glutamine metabolism by inhibitory
desuccinylating GLS [74].
Clearly, the nuclear sirtuins possess a special place in
glucose and lipid metabolism by enhancing or compromis-
ing the specific transcriptional program, while SIRT2 and
mitochondrial sirtuins mainly aim at metabolic enzymes in
response to various nutrient conditions. Most sirtuins are
generally expected to promote catabolism such as
gluconeogenesis and lipid oxidation and counteract anabol-
ism including glycolysis, lipogenesis, adipogenesis and
(See figure on previous page.)
Fig. 3 Overview of sirtuins in lipid metabolism. Selected pathways in nucleus, cytosol and mitochondria are depicted. a Activating LCAD, a key
enzyme in long-chain fatty acids oxidation, SIRT3 increases β-oxidation in hepatocytes and skeletal muscle. Both SIRT3 and SIRT5 promotes
ketogenesis via HMGCS2 in liver. In cytoplasm, SIRT2 deacetylates ACLY and deters lipid synthesis. In contrast to SIRT3, SIRT4 inhibits MCD and
contributes to increased malonyl CoA,which suppresses the fatty acid translocator CAT-1 and shuts down entery of fatty acid for β-oxidation. b
SIRT1 and SIRT6 reduce the activity of nuclear hormone receptor PPARγand lead to decreased adipogenesis. SIRT1 also destabilizes SREBP1 and
transcriptionally represses lipogenesis. Besides the negative regulation, SIRT1 boosts fatty acid oxidation by enhancing PPARα and its coactivator
PGC1α. LCAD, long chain acyl CoA dehydrogenase; HMGCS2,3-hydroxy-3-methylglutaryl CoA synthase 2; ACLY,ATP citrate lyase; MCD,malonyl CoA
decarboxylase; CAT-1,carnitine acyl transferase-1; SREBP1,sterol regulatory element binding protein 1
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glutaminolysis. Consistent with this hypothesis, they are po-
tentially involved in treatment of several metabolic diseases
and even perhaps MYC-driven tumors (mitochondrial
sirtuins).
Sirtuins in DNA repair
The cells are constantly exposed to genomic insults
caused by normal cellular processes or genotoxic agents
such as ultra-violet (UV) and ionizing radiation (IR). To
fight against genomic instability, eukaryotic cells have
developed four major DNA damage response (DDR) path-
ways, including base-excision repair (BER), nucleotide-
excision repair (NER), homologous recombination (HR)
and non-homologous end joining (NHEJ) [75]. BER and
NER are two repair pathways preferentially for single-
strand breaks (SSB) and repair the nucleotides by using
the template sister strand. In contrast, for double-strand
breaks (DSB), cells are prone to choose either HR or
NHEJ. In HR a homologous DNA region from a sister
chromatid is used as a template to reconstitute the dam-
aged area [76], while NHEJ modifies and ligates the
broken DNA ends with little homology [77]. As explained
below, sirtuins have regulated multiple DNA repair path-
ways and efficiently maintained genomic stability (Fig. 4).
SIRT1
Recent studies have highlighted a unique feature of
SIRT1 in regulating DNA damage repair as well as its
role in maintaining telomere length and genomic stabil-
ity [78–80]. Upon genotoxic stress, SIRT1 moves from
silent promoters to sites of DNA damage, deacetylating
histones H1 (Lys26) and H4 (Lys16) and contributing to
the recruitment of DNA damage factors [81–84]. SIRT1
is recruited to DSBs in an ATM kinase-dependent man-
ner [85]. This recruitment is important for r-H2AX foci
formation and accumulation of the DDR-related proteins
such as Rad51, NBS1 and BRCA1 at the breaks.
Important role for SIRT1 in DNA damage repair includes
DSB repair by HR [81, 86–88]. SIRT1 promotes HR by dea-
cetylating WRN, a member of the RecQ DNA helicase fam-
ily with functions in maintenance of genomic stability.
Another studies have reported that SIRT1 interacts with
telomere in vivo and SIRT1 overexpressed mice display in-
creased HR DNA repair throughout the entire genome
[85]. Moreover, SIRT1 is also involved in NHEJ DNA re-
pair. Deacetylation of Ku70 by SIRT1 enhances Ku70-
dependent DNA repair and inhibits mitochondrial apop-
tosis after genotoxic stimuli. SIRT1-dependent KAP1 dea-
cetylation also positively regulates NHEJ [89]. Results
establish the functional significance of KAP1 deacetylation
in the DDR, highlighting a potential SIRT1-KAP1 regula-
tory mechanism for DSB repair that is independent from
modulating the infrastructure of the chromatin. Finally,
SIRT1 can regulate NER by deacetylating and activating
xeroderma pigmentosum A and C proteins (XPA and
XPC) upon UV damage. Deacetylated XPA and XPC
recognize DNA SSBs and recruit other NER factors at the
breaks for DNA repair [85].
Also, hMOF plays an important role in DDR, cell
cycle progression, and cell growth [90, 91]. hMOF
and TIP60, are SIRT1 substrates. The deacetylation
of the enzymatic domains of hMOF and TIP60 by
SIRT1 inhibits their acetyltransferase activity and
promotes ubiquitination-dependent degradation of
these proteins. Immediately following DNA damage,
the binding of SIRT1 to hMOF and TIP60 is transi-
ently interrupted, with corresponding hMOF/TIP60
hyperacetylation. Lysine-to-arginine mutations in
SIRT1-targeted lysines on hMOF and TIP60 repress
DNA DSB repair and inhibit the ability of hMOF/
TIP60 to induce apoptosis in response to DNA DSB.
Together, these findings uncover novel pathways in
which SIRT1 dynamically interacts with and provide










Fig. 4 Nuclear sirtuins regulate genomic stability and their roles in the DDR are summarized. SIRT1 is implicated in diverse DNA repair pathways. SIRT1
promotes HR DNA repair by deacetylating WRN, a DNA helicase. It also regulates NHEJ and NER through Ku70 and XPA and XPC after genotoxic
stimuli. Like SIRT1, SIRT6 modulates DNA repair pathways at multiple layers. SIRT6 affects BER in a PARP1-depdendent manner and recruits DNA-PK to
promote NHEJ. It interacts with two major BER enzymes MYH and APE1 as well. Most recent study uncovered SIRT7 induce NHEJ by recruiting repair
factor 53BP1. XPA and XPC, xeroderma pigmentosum A and C; APE1,Apurinic/apyrimidinic endonuclease 1; DNA-PK,DNA-dependent protein kinase
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SIRT2
SIRT2 is initially illustrated to be implicated in mitotic
progression and function as a cell cycle regulator [92].
Recently several studies highlighted the critical roles of
SIRT2 in genome stability and DDR. During mitosis
SIRT2 maintains genome integrity by deacetylating
CDH1 and CDC20, co-activators of anaphase promoting
complex/cyclosome (APC/C), and regulating APC/C
activity [93]. Through the deacetylation of H4K16Ac and
the histone methyltransferase (HMT) PR-Set7, SIRT2
modulates H4K20 monomethylation deposition that is
paramount in genome stability and DNA repair [94].
Most recently, a study revealed SIRT2 is essential for the
ataxia telangiectasia-mutated and Rad3-related (ATR)
kinase checkpoint pathway (a pathway maintains gen-
ome integrity) and deacetylates CDK9 and ATR-
interacting protein (ATRIP) in response to replication
stress [95, 96].
SIRT3 and SIRT4
SIRT3, SIRT4 and SIRT5, as mentioned above, reside in
the mitochondria, where they control numerous aspects
of mitochondrial metabolism. Beyond metabolic targets,
SIRT3 has been shown to regulate the production of
reactive oxygen species (ROS) from mitochondria by
multiple mechanisms. For example, SIRT3 deacetylates
and activates isocitrate dehydrogenase 2 (IDH2) and
manganese superoxide dismutase (MnSOD) [97], which
maintains cellular ROS homeostasis. SIRT3 also deacety-
lates numerous components of the electron transport
chain, suggesting that SIRT3 could directly suppress
ROS production [98]. In this regard, SIRT3 loss in-
creases cellular ROS levels, contributing to genomic and
mitochondrial DNA instability, and SIRT3 KO mice de-
velop estrogen receptor and progesterone receptor-
positive mammary tumors [99].
The roles and importance of the mtDNA repair mech-
anisms and pathways in the protection against carcino-
genesis, aging, and other human diseases have been
increasingly recognized in the past decade. SIRT3 im-
pacts the repair of mtDNA through its ability to deacety-
late OGG1, a DNA glycosylase important in BER, and
that loss of SIRT3 results in increases of acetylation,
degradation of OGG1 and a decrease of the incision
activity of this enzyme and promotes stress-induced
apoptosis [100].
Importantly, SIRT3 can bind and deacetylate Ku70 in
response to DNA damage [101], suggesting that SIRT3
might be involved in Ku70-dependent DNA repair.
SIRT4 is the most highly induced sirtuins in response
to DNA damage stimuli and represses glutamine con-
sumption without affecting glucose uptake, resulting in a
decrease in the incorporation of glutamine into the
tricarboxylic acid (TCA) cycle intermediates. This
metabolic response contributes to cell cycle arrest of
damaged cells and promotes the repair of damaged
DNA. Indeed, loss of SIRT4 impaired DNA damage-
induced cell cycle arrest and resulted in accumulation of
DNA damage, and SIRT4 KO MEFs possessed more an-
euploidy and exhibited an increased genomic instability.
SIRT6
SIRT6, a NAD + −dependent deacetylase and ADP-
ribosyltransferase, plays a critical role in numerous DNA
repair pathways. The first clues to the function of SIRT6
came from SIRT6 knockout mice. These SIRT6-deficient
mice develop striking degenerative phenotypes and dra-
matic metabolic defects, some of which overlap with
pathologies observed in premature aging [102]. SIRT6
was shown to mediate histone (H3K9, H3K56) deacety-
lation and ultimately maintain the integrity of telomeric
chromatin, defects of which likely accounts for the aging
like phenotype [103, 104]. At the cellular level, SIRT6
deficiency leads to genomic instability and hypersensitiv-
ity to certain forms of genotoxic damage, suggesting its
important role in DDR [105].
SIRT6 was initially proposed to work on BER, because
the DNA damage sensitivities of SIRT6-deficient cells
could be rescued by over-expression of the rate-limiting
enzymes in BER [102]. But the definitive role for SIRT6
in BER remains poorly understood. Recently Xu et al.
has reported that SIRT6 regulates BER in a PARP1-
depdendent manner [106]. H wang et al. further proved
that SIRT6 interacts with and stimulates two major BER
enzymes (MYH and APE1) and also interacts with the
Rad9–Rad1–Hus1 checkpoint clamp which stimulates
almost every enzyme in the BER [107].
Besides BER, SIRT6 is also involved in DNA DSB re-
pair such as HR and NHEJ. McCord et al. demonstrated
that SIRT6 recruits and stabilizes DNA-dependent
protein kinase (DNA-PK) to DSBs in turn promoting
NHEJ repair [108]. SIRT6 also stimulates the poly-ADP-
ribosyltransferase activity of PARP1 (a protein involved
in both double-strand break repair and BER), enhancing
NHEJ and HR DNA repair [109]. In addition, the chro-
matin remodeling factor SNF2H is recruited to DSBs by
SIRT6, which provides proper docking sites for down-
stream DDR factors and allow efficient DNA repair
[110]. Taken together, SIRT6 modulates DNA repair
pathways at multiple layers.
SIRT7
The role of SIRT7 in regulating DNA damage remains
largely dormant for years until recently Vazquez and col-
leagues uncovered a novel function of SIRT7 in DNA re-
pair [111]. They noted that genome homeostasis is
disrupted in the absence of SIRT7 and SIRT7 promotes
DNA repair by deacetylating lysine 18 of histoneH3
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(H3K18Ac) at DNA damage sites and then recruiting
NHEJ repair factor 53BP1.
To conclude, SIRT1 and SIRT6 both pave the way for
DNA repair partly through histone deacetylation at
DNA break sites and then triggering recruitment of mul-
tiple repair factors. Besides the histone modifications,
they also directly modulate non-histone substrates in-
cluding DNA repair enzymes and other repair factors.
When it comes to mitochondrial sirtuins, things turn
out to be more intriguing. SIRT3 affects the genome and
mitochondrial DNA stability by maintaining ROS
homeostasis and even participate in the mtDNA repair
pathways. And SIRT4 is appreciated to ensure proper
DNA repair by dampening glutamine metabolism and
initiating cell cycle arrest.
Sirtuins in cancer
It’s now widely believed that sirtuins regulate numerous
processes that appear to be awry in cancer cells. The
function of sirtuins are characterized as tumor suppres-
sor and/or oncogene, depending on various genetic con-
text, tumor type and stage. As detailed below, we mainly
focus on the regulatory roles of sirtuins regarding DNA
repair and cancer-related metabolism.
SIRT1
SIRT1’s role in carcinogenesis appears to be opposing
and complicated. On one hand, SIRT1 was found to
be tumorigenic in various human cancer [112–117],
which is consistent with its anti-apoptotic activities
via p53 and FOXO transcription factors in response
to stress [118]. In parallel, SIRT1 was shown to exert
an essential role toward the oncogenic signaling me-
diated by the estrogen receptor-α (ERα) in breast can-
cer cells [119].
On the other hand, a collection of in vivo mouse
models provided evidence that SIRT1 maintains genetic
stability in normal cells and decelerates tumor formation
[81, 115, 120]. Indeed, a decreased SIRT1 level in breast
cancer is associated with BRCA1 mutations, suggesting
it as a tumor suppressor. This anti-cancerogenic role
could be explained by SIRT1-mediated suppression of
the antiapoptotic gene survivin and it is also compatible
with SIRT1’s genome stabilizing functions [121]. Inter-
estingly, SIRT1 turned out to be transcriptionally up-
regulated by BRCA1, which is best known for its central
role as a surveillance factor in DSB repair [122].
Accordingly, this context-dependent role of SIRT1
represents a target for selective killing of cancer ver-
sus non-cancer cells [123], and a recent drug screen-
ing approach has led to the identification of a potent
SIRT1/2 inhibitory substance with potential use in
cancer therapy [124].
SIRT2
Given the fact SIRT2 maintains genomic stability as dis-
cussed above, this sirtuin mainly functions as a tumor
suppressor. Notably, it has been revealed that SIRT2 is
also linked with cancer metabolism and promotes tumor
growth. SIRT2 can regulate the activities of HIF-1α, phos-
phoglycerate mutase (PGAM) and glucose-6-phosphate
dehydrogenase (G6PD) [125–127], which either stimulates
glycolytic energy production or coordinates glycolysis and
biomass production.
Decreased expression of SIRT2 can be observed in gli-
oma, liver cancer, and esophageal and gastric adenocar-
cinomas [128, 129]. By contrast, SIRT2 has negative
implications in certain types of cancer including acute
myeloid leukemia [130], pancreatic cancer, neuroblast-
oma [131], high-grade human HCC and prostate cancer
[132, 133]. Interestingly, SIRT2 functions as both tumor
suppressor and oncogene dependent on different tumor
grade in breast cancer [134].
SIRT3
SIRT3 appears to be a tumor suppressor mainly through
its ability to repress reactive oxygen species (ROS) and
HIF-1α [34, 135], which fights against metabolic switch
towards aerobic glycolysis. In line with this, up-regulation
of SIRT3 inhibited the cell growth of oral squamous cell
carcinoma (OSCCs) and decreased the levels of basal re-
active oxygen species (ROS) in both OSCC lines [136].
Furthermore, a recent study revealed that SIRT3 nega-
tively regulates pancreatic tumor growth by restraining
malate-aspartate NADH shuttle, which is critical to sus-
tain glycolysis in tumor cells, via deacetylating glutamate
oxaloacetate transaminase (GOT2) [137]. However, in spe-
cific type of cancer, SIRT3 turns out to be an oncogene
and promote tumorigenensis [138, 139].
SIRT4
SIRT4 mRNA level was reduced in several human can-
cers, such as small cell lung carcinoma [140], gastric
cancer [141], breast cancer and leukemia [142]. And
lower SIRT4 expression is associated with shorter sur-
vival time in lung tumor patients [143]. A recent study
has also showed that SIRT4 is a crucial regulator of the
stress resistance in cancer cells and SIRT4 loss sensitizes
cells to DNA damage or ER stress [144]. Indeed, the ac-
tivation of mammalian target of rapamycin complex 1
(mTORC1) has been demonstrated to be associated with
increased glutamine metabolism through mechanically
inhibiting SIRT4 [16].
Simply put, by reducing the activity of GDH, SIRT4
elicits the inhibition of glutamine anaplerosis and the
attendant halt of cell proliferation that provides oppor-
tunity for DNA damage repair. Therefore, SIRT4 may
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attenuate the tumorigenesis by repressing glutamine me-
tabolism and/or genomic instability [145–147].
SIRT5
SIRT5 has been considered as a potential oncogene by
suppressing PDH, which may facilitate aerobic glycolysis
[148]. In support of this notion, SIRT5 is overexpressed
in non-small cell lung cancer [149] and ovarian carcin-
oma [150]. In accord with other sirtuins, SIRT5 is also
emerged as a tumor suppressor in squamous cell carcin-
oma [151] and endometrial carcinoma [152].
SIRT6
SIRT6 is regarded as a tumor suppressor partly due to
its pivotal role in cancer metabolism. Studies show
SIRT6 represses aerobic glycolysis in cancer cells and
SIRT6 deficiency contributes to tumor formation even
without any oncogene activation [153], indicating the
glucose metabolic reprogramming is not a mere conse-
quence of tumorigenesis but also one of its main drivers.
The avid glucose take up in SIRT6-deficient cells is due
to the fact that SIRT6 binds and co-represses HIF-1α
transcriptional activity which suppresses the expression
of several key glycolytic genes [42]. In addition, loss of
SIRT6 leads to the increasing glutamine metabolism and
ribosomal gene expression which are the later events in
the tumorigenic process. Decreased H3K56 deacetylation
at the promoter region by SIRT6 might account for that
[153]. Recently Zhang et al. show that SIRT6 inhibits
hepatic gluconeogenesis via interacting with p53 and
promotes glucose homeostasis [154].
As with SIRT1, SIRT6 plays both tumor suppressing
and promoting roles. SIRT6 expression is downregulated
in head and neck squamous cell carcinoma, colon, pancre-
atic, liver and non-small cell lung cancers [151, 155–157].
Conversely, increased SIRT6 expression has been reported
in human skin squamous cell carcinoma and pancreatic,
prostate and breast cancers, which suggests a poor prog-
nosis and chemotherapy resistance [158–161].
SIRT7
Although received comparatively less attention than
other sirtuins, SIRT7 appears to have several features
that are critical for human cancers. Recent studies
reported that SIRT7 has tumor promoting activities. In
this regard, SIRT7 is found to be an oncogene in
hepatocellular carcinoma, gastric cancer and colorectal
cancer, and depletion of SIRT7 suppresses tumor growth
[162–164]. Strikingly, overexpression of this sirtuin pro-
tects tumor cells against genotoxic damage and facili-
tates cell survival, suggesting the possibility that SIRT7
acts an oncogenic role by enhancing genome integrity in
tumor cells [165].
To sum up, the dichotomous roles of sirtuins in cancer
largely revolve around their functions in DNA damage
response and cancer metabolism. In general, tumor-
suppressive sirtuins inhibit metabolic shift to glycolysis
and glutaminolysis, which are both distinct metabolic
changes in cancer cells. And they are engaged in tumori-
genesis partly through inducing aerobic glycolysis or sus-
taining genome stability in tumor cells.
Conclusions
Extensive studies over the past few years have pointed
out that sirtuins are involved in processes including en-
ergy metabolism, genome integrity and carcinogenesis.
Remarkably, several sirtuins play a dual role in cancer
depending on various tumor types, stages and micro-
environment. Thus, deciphering the underlying mecha-
nisms and conditions which enabling their opposing role
in cancer may be one of the main challenges and of tre-
mendous therapeutic significance. Also, further work
will be needed to dissect whether or how sirtuins con-
nect and coordinate different hallmarks of cancer such
as genomic instability, deregulated cell metabolism and
aberrant tumor microenvironment.
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